P/E at 34.41 vs Industry's 33.41: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflects Market Nuance

The current P/E of 34.41 for Sun Pharmaceutical Industries Ltd sits just above the industry average of 33.41, indicating a modest valuation premium. This premium suggests that investors are willing to pay slightly more for the stock relative to its sector, possibly reflecting confidence in its earnings stability or growth prospects. However, the premium is not excessive, implying that the market is not overly optimistic compared to peers. The sector itself has a broad range of valuations, with some stocks trading at significant discounts or premiums, so this positioning is relatively balanced. Sun Pharma's valuation premium invites the question: previously rated Hold, what is Sun Pharmaceutical Industries Ltd's current rating?

Performance Across Timeframes: A Tale of Divergence

Examining the stock's returns reveals a divergence between short-term and longer-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has gained 7.19%, a notable outperformance compared to the Sensex's 10.58% decline during the same period. This positive annual return contrasts with the more subdued short-term figures: the stock is down 2.52% over the last month and has barely moved over the past three months, registering a marginal 0.10% gain. This suggests that while the stock has shown resilience over the medium term, recent momentum has stalled. The 1-week and 1-day performances are positive but modest, with gains of 0.26% and 0.96% respectively, outperforming the Sensex's declines in those periods.

This mixed momentum raises the analytical question: is the recent short-term weakness a pause in an ongoing uptrend or a sign of deeper challenges ahead?

Moving Average Configuration: Signs of a Complex Technical Picture

The technical setup of Sun Pharmaceutical Industries Ltd offers further insight into its current trend dynamics. The stock is trading above its 50-day, 100-day, and 200-day moving averages, indicating strength over the medium and long term. However, it remains below its 5-day and 20-day moving averages, signalling some short-term pressure or consolidation. This configuration often suggests a recent pullback or pause within a broader uptrend, rather than a full reversal. The stock's ability to hold above the longer-term averages may provide a technical floor, but the short-term weakness could reflect profit-taking or sector-specific headwinds. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Relative Performance: Outperforming Sensex Over Multiple Horizons

Looking beyond the one-year horizon, Sun Pharmaceutical Industries Ltd has demonstrated strong relative performance versus the Sensex. Over three years, the stock has surged 82.42%, compared to the Sensex's 16.94%. The five-year return is even more pronounced, with a gain of 165.26% against the Sensex's 40.60%. However, the 10-year return of 143.85% trails the Sensex's 172.00%, indicating some relative underperformance over the longer term. This pattern suggests that the stock has been a strong performer in recent years but has lagged the broader market over the past decade. The question arises: should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 6 posted negative results. This distribution indicates a generally favourable environment for the sector, though not without pockets of weakness. Sun Pharmaceutical Industries Ltd, as a large-cap player, appears to be navigating this environment with relative stability, reflected in its modest valuation premium and steady performance. The sector's mixed results may be contributing to the stock's short-term consolidation phase.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 67.0. The rating was updated on 1 June 2026, now classified as Hold. This reassessment reflects the evolving data landscape, including valuation, performance, and technical indicators. The shift from Buy to Hold suggests a more cautious stance, balancing the stock's strengths against recent momentum and sector dynamics. What does this updated rating imply for current and prospective shareholders?

Conclusion: A Balanced Data-Driven Perspective

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight valuation premium with solid medium-term performance but mixed short-term momentum. Its technical setup suggests a recent pause within a longer-term uptrend, while sector results remain broadly positive but varied. The reassessment from Buy to Hold reflects these nuances, signalling a more measured view of the stock's current standing. Investors may find value in analysing these multiple dimensions before making decisions, especially given the stock's relative outperformance over one and three years but modest recent consolidation.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →